Brain Scans Reveal Long COVID Symptoms Tied to Emotion Centers Not Inflammation
New PET imaging finds no widespread brain inflammation in long COVID patients — pointing instead to heightened activity in stress and emotion regions.
Summary
A University of Turku brain imaging study challenges the leading theory that long COVID is caused by ongoing brain inflammation. Researchers scanned 14 long COVID patients, 11 healthy controls, and 13 multiple sclerosis patients using PET and MRI technology. They found no significant difference in neuroinflammation between long COVID patients and healthy volunteers. Instead, patients with worse symptoms showed increased activity in the hippocampus and amygdala — brain regions governing memory, emotion, and stress response. Earlier scans suggested inflammation may be present in the first 16 months post-infection but fades over time. These findings suggest that for many long COVID sufferers, the brain's emotional processing system — not runaway inflammation — may be driving persistent fatigue, brain fog, anxiety, and depression.
Detailed Summary
Long COVID has affected millions of people worldwide, with symptoms like fatigue, brain fog, anxiety, and depression persisting for months or years after initial infection. One of the most popular scientific explanations has been that SARS-CoV-2 triggers sustained inflammation in the brain. A new study from the University of Turku in Finland directly tested this hypothesis using advanced brain imaging — and the results were surprising.
Researchers used PET scans capable of detecting neuroinflammation alongside structural MRI scans in 14 long COVID patients, 11 healthy volunteers, and 13 people with multiple sclerosis, a disease defined by brain inflammation. Blood markers of neuronal damage were also analyzed. Crucially, long COVID patients showed far less inflammatory activity than MS patients and no meaningful difference from healthy controls — directly contradicting the inflammation hypothesis.
One nuanced finding: participants scanned within 16 months of infection showed modestly higher white matter inflammatory activity than those scanned later. This suggests brain inflammation may occur earlier in the disease course but resolves over time, which could explain why some earlier studies detected it while this one largely did not.
Perhaps the most significant discovery was a link between symptom severity and activity in the hippocampus and amygdala — brain structures central to emotional regulation, memory, and stress responses. Patients reporting higher anxiety, depression, and lower quality of life showed elevated cellular activity in these regions, pointing toward a neurological stress-response mechanism rather than immune-driven inflammation as the primary driver of chronic symptoms.
For health-conscious individuals and clinicians, these findings reframe long COVID management. Interventions targeting brain stress regulation — such as cognitive behavioral therapy, nervous system regulation practices, or treatments addressing mood and emotional processing — may be more relevant than anti-inflammatory strategies for many patients. The study is small and further research is needed to confirm these patterns across larger populations.
Key Findings
- No significant brain inflammation detected in long COVID patients compared to healthy controls via PET imaging
- Hippocampus and amygdala showed increased activity in patients with worse anxiety, depression, and quality of life
- Brain inflammation may be present early post-infection but appears to diminish within 16 months
- Long COVID neurological burden was substantially lower than in multiple sclerosis patients
- Findings suggest emotional stress-response pathways, not inflammation, may drive many long COVID symptoms
Methodology
This is a research summary reporting on a peer-reviewed imaging study from the University of Turku, a credible academic institution. The study used gold-standard PET and MRI neuroimaging with blood biomarkers, but the sample size is small at 14 long COVID participants, limiting generalizability. Source is ScienceDaily summarizing institutional findings; primary journal publication should be consulted for full methodology.
Study Limitations
The study included only 14 long COVID patients, making it underpowered to draw definitive conclusions. It is unclear which long COVID variants or severity levels were represented, and the article does not specify the journal of publication. Findings should be validated in larger, longitudinal cohorts before changing clinical practice.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.